CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma.
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
维持治疗在胰腺导管腺癌（PDAC）中很少被考虑。我们描述了一例57岁转移性PDAC男性患者，因无法耐受神经毒性，初始接受全剂量联合化疗，随后减量。在对肝转移灶行射频消融联合对胰腺肿瘤行放疗达到完全缓解后，化疗终止并应用维持治疗：初始为nivolumab联合细胞因子诱导的杀伤细胞治疗，随后为nivolumab单药减量给药间隔。在超过2年的nivolumab治疗期间未发生不良事件，患者目前仍无病生存期。迄今为止，这是首例在转移性PDAC成功多模式治疗后应用维持nivolumab的报道。
Maintenance therapy is rarely considered in pancreatic ductal adenocarcinoma (PDAC).
We describe the case of a 57-year-old man with metastatic PDAC treated with an initially full but subsequently de-escalated dose of combination chemotherapy due to intolerance to neurotoxicity. After a complete response to combined radiofrequency ablation for the liver metastasis and radiotherapy for the pancreatic tumor was achieved, chemotherapy was terminated and maintenance therapy was applied: nivolumab plus cytokine-induced killer cell therapy initially and then a de-escalated dosing interval of nivolumab monotherapy subsequently.
No adverse events occurred during nivolumab therapy for more than 2 years, and the patient remains disease-free. To date, this is the first report of maintenance nivolumab after successful multimodality therapy in metastatic PDAC.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
